ArticleAnti-cancer drugs2026

A novel anticancer natural product SP09 selectively targets KRAS-mutant NSCLC through LKB1/AMPK/mTOR modulation: implications for novel therapeutic development.

Peng Yue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.